Sol-Gel Technologies ROA 2016-2024 | SLGL

Current and historical return on assets (ROA) values for Sol-Gel Technologies (SLGL) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Sol-Gel Technologies ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2024-09-30 $-0.01B $0.04B -21.18%
2024-06-30 $-0.02B $0.04B -33.90%
2024-03-31 $-0.02B $0.04B -48.42%
2023-12-31 $-0.03B $0.05B -56.28%
2023-09-30 $-0.03B $0.05B -57.71%
2023-06-30 $-0.03B $0.06B -51.49%
2023-03-31 $-0.02B $0.05B -39.60%
2022-12-31 $-0.02B $0.05B -28.71%
2022-09-30 $0.01B $0.05B 8.66%
2022-06-30 $0.01B $0.06B 15.45%
2022-03-31 $0.00B $0.06B 1.79%
2021-12-31 $0.00B $0.07B 5.41%
2021-09-30 $-0.02B $0.05B -32.08%
2021-06-30 $-0.03B $0.05B -48.00%
2021-03-31 $-0.03B $0.05B -40.94%
2020-12-31 $-0.03B $0.06B -41.88%
2020-09-30 $-0.03B $0.07B -43.01%
2020-06-30 $-0.03B $0.08B -39.86%
2020-03-31 $-0.03B $0.08B -38.66%
2019-12-31 $-0.03B $0.06B -38.46%
2019-09-30 $-0.03B $0.07B -44.61%
2019-06-30 $-0.03B $0.06B -43.97%
2019-03-31 $-0.03B $0.07B -43.28%
2018-12-31 $-0.03B $0.07B -40.37%
2018-03-31 $-0.01B $0.09B -42.48%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.012B $0.002B
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $24.142B 7.92
Dr Reddy's Laboratories (RDY) India $12.621B 24.15
BridgeBio Pharma (BBIO) United States $4.953B 0.00
Bausch Health Cos (BHC) Canada $2.672B 1.97
Supernus Pharmaceuticals (SUPN) United States $1.975B 26.90
Amphastar Pharmaceuticals (AMPH) United States $1.894B 11.38
Taysha Gene Therapies (TSHA) United States $0.379B 26.43
Personalis (PSNL) United States $0.372B 0.00
Assembly Biosciences (ASMB) United States $0.100B 0.00
Evoke Pharma (EVOK) United States $0.008B 0.00
Teligent (TLGT) United States $0.000B 0.00